Protalix BioTherapeutics, Inc. – AMEX:PLX
Protalix BioTherapeutics stock price today
$1.53
-0.30
-16.39%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 13 hours
Protalix BioTherapeutics stock price monthly change
+60.53%
month
Protalix BioTherapeutics stock price quarterly change
+60.53%
quarter
Protalix BioTherapeutics stock price yearly change
+1.10%
year
Protalix BioTherapeutics key metrics
Market Cap | 126.64M |
Enterprise value | 130.27M |
P/E | -7.34 |
EV/Sales | 2.73 |
EV/EBITDA | -11.39 |
Price/Sales | 2.39 |
Price/Book | -10.70 |
PEG ratio | -0.14 |
EPS | 0.11 |
Revenue | 59.65M |
EBITDA | 9.22M |
Income | 6.84M |
Revenue Q/Q | -60.90% |
Revenue Y/Y | 44.99% |
Profit margin | -31.33% |
Oper. margin | -27.32% |
Gross margin | 58.87% |
EBIT margin | -27.32% |
EBITDA margin | 15.47% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeProtalix BioTherapeutics stock price history
Protalix BioTherapeutics stock forecast
Protalix BioTherapeutics financial statements
| Jun 2023 | 35.07M | 19.33M | 55.14% |
|---|---|---|---|
| Sep 2023 | 10.34M | -1.85M | -17.9% |
| Dec 2023 | 10.48M | -6.04M | -57.64% |
| Mar 2024 | 3.74M | -4.59M | -122.6% |
| 2025 | 101.4M | 54.59M | 53.84% |
|---|---|---|---|
| 2026 | 167.2M | 99.88M | 59.74% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 88417000 | 49.41M | 55.89% |
|---|---|---|---|
| Sep 2023 | 87569000 | 49.32M | 56.32% |
| Dec 2023 | 84434000 | 50.86M | 60.24% |
| Mar 2024 | 89825000 | 60.03M | 66.84% |
| Jun 2023 | 4.97M | -222K | 10.43M |
|---|---|---|---|
| Sep 2023 | -6.88M | -20.87M | 0 |
| Dec 2023 | 3.59M | -342K | 0 |
| Mar 2024 | 4.18M | -606K | 0 |
Protalix BioTherapeutics alternative data
| Aug 2023 | 193 |
|---|---|
| Sep 2023 | 193 |
| Oct 2023 | 193 |
| Nov 2023 | 193 |
| Dec 2023 | 193 |
| Jan 2024 | 193 |
| Feb 2024 | 193 |
| Mar 2024 | 208 |
| Apr 2024 | 208 |
| May 2024 | 208 |
| Jun 2024 | 208 |
| Jul 2024 | 208 |
Protalix BioTherapeutics other data
4.13%
-3.07%
of PLX is owned by hedge funds
2.00M
-1.55M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jan 2023 | 110000 | 0 |
| Oct 2023 | 64516 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | BASHAN DROR director, officer.. | Common Stock | 16,129 | $1.41 | $22,742 | ||
Purchase | BASHAN DROR director, officer.. | Common Stock | 48,387 | $1.4 | $67,742 | ||
Purchase | SCHWARTZ AHARON director | Common Stock | 110,000 | $1.42 | $155,870 | ||
Purchase | BASHAN DROR director, officer.. | Common Stock | 68,000 | $1.5 | $102,000 | ||
Sale | DEXCEL PHARMA TECHNOLOGIES LTD. 10 percent owner | Common Stock | 857,506 | $2.25 | $1,931,961 | ||
Sale | DEXCEL PHARMA TECHNOLOGIES LTD. 10 percent owner | Common Stock | 61,211 | $2.56 | $156,578 | ||
Purchase | SCHWARTZ AHARON director | Common Stock | 64,000 | N/A | N/A | ||
Purchase | MANOR MOSHE director, officer: President & .. | Common Stock | 50,000 | N/A | N/A | ||
Sale | CAMBER CAPITAL MANAGEMENT LLC 10 percent owner | Common Stock | 2,500,000 | N/A | N/A | ||
Option | SHAALTIEL YOSEPH officer: Executive VP, R&D | Stock Options (Right to Buy) | 122,162 | N/A | N/A |
| Quarter | Transcript |
|---|---|
| Q1 2024 10 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 14 Mar 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 6 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 7 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Dr. Einat Brill-Almon (1960) Senior Vice President & Chief Devel. Officer | $665,700 |
| Mr. Dror Bashan (1967) Pres, Chief Executive Officer & Director | $599,390 |
Mr. Eyal Rubin M.B.A. (1976) Senior Vice President, Chief Financial Officer, Treasurer & Corporation Sec. | $494,880 |
Amicus Therapeutics: The Right Play Now
Protalix BioTherapeutics Stock: FDA Approval For Elfabrio To Drive Profitability
Protalix Undervalued On CHMP Recommendation Of PRX-102 For Fabry Disease
The Prognosis For Protalix BioTherapeutics
BioMarin: More Growth
BioMarin: A Good Anchor For Your Biotech Portfolio
Amicus Therapeutics: An Inflection Point In Growth
Protalix Biotherapeutics: Is It Worth The Wait?
The Best Of Backtesting - Week Oct. 4
-
What's the price of Protalix BioTherapeutics stock today?
One share of Protalix BioTherapeutics stock can currently be purchased for approximately $1.53.
-
When is Protalix BioTherapeutics's next earnings date?
Unfortunately, Protalix BioTherapeutics's (PLX) next earnings date is currently unknown.
-
Does Protalix BioTherapeutics pay dividends?
No, Protalix BioTherapeutics does not pay dividends.
-
How much money does Protalix BioTherapeutics make?
Protalix BioTherapeutics has a market capitalization of 126.64M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 37.48% to 65.49M US dollars.
-
What is Protalix BioTherapeutics's stock symbol?
Protalix BioTherapeutics, Inc. is traded on the AMEX under the ticker symbol "PLX".
-
What is Protalix BioTherapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Protalix BioTherapeutics?
Shares of Protalix BioTherapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Protalix BioTherapeutics's key executives?
Protalix BioTherapeutics's management team includes the following people:
- Dr. Einat Brill-Almon Senior Vice President & Chief Devel. Officer(age: 65, pay: $665,700)
- Mr. Dror Bashan Pres, Chief Executive Officer & Director(age: 58, pay: $599,390)
- Mr. Eyal Rubin M.B.A. Senior Vice President, Chief Financial Officer, Treasurer & Corporation Sec.(age: 49, pay: $494,880)
-
How many employees does Protalix BioTherapeutics have?
As Jul 2024, Protalix BioTherapeutics employs 208 workers.
-
When Protalix BioTherapeutics went public?
Protalix BioTherapeutics, Inc. is publicly traded company for more then 27 years since IPO on 15 May 1998.
-
What is Protalix BioTherapeutics's official website?
The official website for Protalix BioTherapeutics is protalix.com.
-
Where are Protalix BioTherapeutics's headquarters?
Protalix BioTherapeutics is headquartered at 2 University Plaza, Hackensack, NJ.
-
How can i contact Protalix BioTherapeutics?
Protalix BioTherapeutics's mailing address is 2 University Plaza, Hackensack, NJ and company can be reached via phone at +20 16969345.
Protalix BioTherapeutics company profile:
Protalix BioTherapeutics, Inc.
protalix.comExchange:
AMEX
Full time employees:
208
Industry:
Biotechnology
Sector:
Healthcare
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in the last stage of clinical trials for the treatment of Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is based in Hackensack, New Jersey.
2 University Plaza
Hackensack, NJ 07601
Hackensack, NJ 07601
CIK: 0001006281
ISIN: US74365A3095
CUSIP: 74365A309
